EssilorLuxottica acquires RetinAI, a medical technology company specializing in AI and data management for the optical sector. This acquisition strengthens EssilorLuxottica’s med-tech strategy, integrating advanced software based on machine learning and computer vision to improve clinical, research, and pharmaceutical processes. RetinAI’s technologies enhance clinical solutions based on AI, benefiting patients by improving care quality and experience. RetinAI’s platform, RetinAI Discovery, approved by the FDA and CE certified, uses AI models to monitor diseases like AMD, diabetic retinopathy, and glaucoma for early diagnosis and targeted interventions. Collaboration with pharmaceutical companies and research institutes accelerates clinical studies and drug development processes.

Francesco Milleri, EssilorLuxottica’s CEO, highlights the transformative potential of AI in converting clinical data into insights for more accurate and timely diagnoses. This acquisition marks a significant milestone for RetinAI, enabling the global impact of their technology in improving patient care paths through efficient solutions. Carlos Ciller, RetinAI’s CEO, emphasizes the power of data and AI in reshaping patient care journeys and looks forward to collaborating with EssilorLuxottica to enhance eye care and patient experiences worldwide.

Read more at GlobeNewswire: EssilorLuxottica acquisisce RetinAI e accelera sullo